Table 1 Characteristics of ovarian cancer (OC) patients in the discovery and validation cohort.
From: Serum anti-CFL1, anti-EZR, and anti-CYPA autoantibody as diagnostic markers in ovarian cancer
Variables | Discovery cohort | Validation cohort | BD validation cohort | ||||
|---|---|---|---|---|---|---|---|
OC (%) | NC (%) | OC (%) | NC (%) | OC (%) | NC (%) | BD (%) | |
Number | 70 | 70 | 128 | 128 | 81 | 81 | 81 |
Female | 70 (100) | 70 (100) | 128 (100) | 128 (100) | 81 (100) | 81 (100) | 81 (100) |
Age, years* | |||||||
 Mean ± SD | 53.3 ± 11.4 | 52.2 ± 11.8 | 52.7 ± 9.6 | 51.1 ± 9.8 | 45.9 ± 10.1 | 45.6 ± 10.1 | 44.2 ± 10.3 |
 Range | 19–73 | 20–76 | 22–81 | 23–83 | 19–68 | 20–69 | 20–68 |
FIGO | |||||||
 I | 9 (12.8) |  | 16 (12.5) |  |  |  |  |
 II | 9 (12.8) |  | 16 (12.5) |  |  |  |  |
 III | 33 (47.1) |  | 51 (39.8) |  |  |  |  |
 IV | 12 (17.1) |  | 32 (25.0) |  |  |  |  |
 Unknown | 7 (10.0) |  | 13 (10.1) |  |  |  |  |
Histologic type | |||||||
 Epithelial tumor | 54 (77.1) |  | 107 (83.5) |  |  |  |  |
 Sexual cord interstitial tumor | 2 (2.8) |  | 7 (5.4) |  |  |  |  |
 Germ cell tumor | 4 (5.7) |  | 4 (3.0) |  |  |  |  |
 Unknown | 10 (14.2) |  | 10 (7.8) |  |  |  |  |
Lymph node metastasis | |||||||
 Yes | 43 (61.4) |  | 76 (59.3) |  |  |  |  |
 No | 22 (31.4) |  | 36 (28.1) |  |  |  |  |
 Unknown | 5 (7.1) |  | 16 (12.5) |  |  |  |  |
Distant metastasis | |||||||
 Yes | 12 (17.1) |  | 32 (25.0) |  |  |  |  |
 No | 54 (77.1) |  | 85 (66.4) |  |  |  |  |
 Unknown | 4 (5.7) |  | 11 (8.5) |  |  |  |  |
Menopause | |||||||
 Yes | 56 (80.0) |  | 101 (78.9) |  |  |  |  |
 No | 10 (14.2) |  | 21 (16.4) |  |  |  |  |
 Unknown | 4 (5.7) |  | 6 (4.6) |  |  |  |  |
